|NCPE Assessment Process Complete
|For the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|The NCPE believe that apixaban is cost effective for the prevention of VTE following total hip replacement and total knee replacement.